Translating and field-validating an epigenetic blood test to predict TB infection and disease risk

We will deliver a validated DNA blood test which can be used to identify asymptomatic individuals in at-risk communities who are infected with the tuberculosis bacteria and at risk of developing symptomatic disease over 3 years. Community screening asymptomatic individuals with this test has the potential to have the greatest impact on reducing TB cases, by allowing us to better target preventative therapy to those most in need, before they develop disease and transmit the bacteria to others.